CEACAM-5 protein: from a classic tumor marker to an emerging cancer therapeutic target

Abstract

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM-5), more widely known as carcinoembryonic antigen (CEA), is a highly glycosylated cell surface glycoprotein belonging to the carcinoembryonic antigen subgroup of the immunoglobulin superfamily. As one of the most iconic biomarkers in human cancer history, CEACAM-5 exhibits highly restricted expression in normal adult tissues but is significantly overexpressed in various epithelial-derived malignancies, particularly in colorectal cancer, non-small cell lung cancer, and gastric cancer. Its unique expression pattern has made it play a central role for decades in tumor diagnosis, prognosis evaluation, and treatment monitoring. Today, with the rapid development of antibody engineering and immunotherapy technologies, CEACAM-5 is transitioning from an important diagnostic marker to a highly promising cancer therapeutic target, leading the development of new-generation antibody-drug conjugates, bispecific antibodies, and cell therapies.

I. Molecular Analysis: Structure and Function of CEACAM-5

1.1 Structural and Expression Characteristics

CEACAM-5 is a type I transmembrane glycoprotein with a molecular weight of approximately 180-200 kDa, which varies due to high glycosylation.

Domains:

Extracellular region: Contains seven immunoglobulin-like domains (one N-terminal IgV-like domain and six IgC2-like domains). The IgV domain mediates homophilic and heterophilic interactions and is the key region for ligand binding and intercellular recognition (homophilic and heterophilic binding).

Transmembrane region

Cytoplasmic tail: Very short (only 27 amino acids), lacking known signaling motifs, suggesting that its main function relies on forming complexes with other transmembrane proteins (such as CEACAM-1) to transmit signals.

Expression pattern:

Normal physiology: Expressed in the intestinal, pancreatic, and liver epithelia during embryonic development. In healthy adults, it is expressed at very low levels only in colonic crypt epithelial cells and some gastric mucosal cells.

Pathological states: Commonly abnormally overexpressed in adenocarcinomas, including colorectal cancer (80-90%), non-small cell lung cancer (approximately 50-70%), gastric cancer (60-70%), pancreatic cancer, and breast cancer.

1.2 Core Biological Functions

The functions of CEACAM-5 are complex and play multiple roles in tumorigenesis and progression:

Cell adhesion and recognition: Through homophilic binding, it mediates tumor cell aggregation, potentially promoting tumor clumping; through heterophilic binding with other CEACAM family members, it affects the interaction between tumor cells and other cells in the microenvironment.

Inhibition of cell differentiation and polarity: In intestinal epithelial cells, its abnormal expression disrupts cell polarity and interferes with normal differentiation programs.

Promotion of tumor metastasis:

Inhibition of anoikis: Helps tumor cells detached from the primary site survive in circulation.

Mediation of pre-metastatic niche formation: Acts as a signaling molecule, affecting stromal cells in distant organs to pave the way for metastasis.

Immune regulation: Can bind to and activate CEACAM-1 expressed on myeloid cells (such as neutrophils and macrophages), transmitting inhibitory signals to suppress the killing function of immune cells, thereby helping tumor cells achieve immune escape. This mechanism makes it an ideal target for immunotherapy.

II. Core Associated Diseases: Diagnostic and Therapeutic Focus in Epithelial Cancers

2.1 Colorectal Cancer (CRC)------ Classic Core Area

"Gold standard" serum biomarker: Since its discovery in 1965, serum CEA testing has been a cornerstone in postoperative management, recurrence monitoring, and efficacy evaluation for CRC. Elevated preoperative levels are associated with more advanced stages; failure of postoperative levels to decline or subsequent elevation during follow-up is a sensitive indicator of tumor recurrence or metastasis.

Clinical limitations: Due to its potential mild elevation in inflammatory diseases (such as colitis) and insufficient sensitivity for early-stage CRC (approximately 30-40%), it is not recommended as a screening tool for the general population.

2.2 Other Gastrointestinal Tumors

Gastric cancer: An important prognostic marker and treatment monitoring indicator.

Pancreatic cancer: Often combined with CA19-9 testing to aid diagnosis and monitoring.

Hepatocellular carcinoma: Serum CEA levels are elevated in some patients, particularly in mixed-type cholangiocarcinoma.

2.3 Non-Small Cell Lung Cancer (NSCLC)

Major subtypes: Highly expressed in lung adenocarcinoma.

Prognostic significance: High serum CEA levels are an independent poor prognostic factor.

Treatment guidance: Can be used to monitor the efficacy of targeted or immunotherapy.

2.4 Breast Cancer

Especially in metastatic breast cancer, serum CEA levels can be used to monitor disease progression.

2.5 Non-Malignant Diseases

Benign inflammation: Conditions such as ulcerative colitis, pancreatitis, and cirrhosis can cause transient mild elevation of serum CEA, requiring careful differentiation.

III. Translational Applications: Paradigm Shift from Diagnosis to Therapy

3.1 Diagnosis, Prognosis, and Monitoring (Mature Applications)

Serological testing: Quantitative monitoring of serum CEA levels through methods such as chemiluminescent immunoassay (CLIA) is one of the most routine tests in clinical oncology.

Histopathology: Immunohistochemical (IHC) staining confirms CEACAM-5 expression in tumor tissues, aiding in diagnosis (e.g., determining adenocarcinoma origin) and guiding targeted treatment decisions.

3.2 Emerging Strategies as a Therapeutic Target (Frontier Directions)

Given its widespread and high expression in tumors but limited expression in normal tissues, CEACAM-5 has become a hot candidate target for tumor-targeted therapy.

Antibody-drug conjugates (ADCs):

Mechanism: Highly specific anti-CEACAM-5 monoclonal antibodies are conjugated with potent cytotoxic drugs to achieve precise "bombing."

Representative drug: SAR408701 (Tusamitamab ravtansine) is a CEACAM-5-targeted ADC with the microtubule inhibitor DM4 as its payload. It has shown promising antitumor activity in clinical trials for advanced non-squamous NSCLC and gastric cancer with high CEACAM-5 expression.

Bispecific antibodies (BsAbs):

Mechanism: One arm binds CEACAM-5 on tumor cells, while the other arm binds CD3 on T cells, redirecting T cells to the tumor site to elicit killing.

Representative drug: Cibisatamab (CEA-TCB) has shown efficacy in early clinical studies for solid tumors such as colorectal cancer but also faces challenges like cytokine release syndrome (CRS).

Chimeric antigen receptor T-cell (CAR-T) therapy:

Progress: CEACAM-5-targeted CAR-T therapies are being explored in preclinical and early-phase (Phase I) clinical trials, primarily for treating colorectal and gastric cancers. Challenges include overcoming solid tumor microenvironment barriers and managing potential "off-target" toxicity.

Radioimmunotherapy and imaging:

Application: Conjugating radionuclides to anti-CEACAM-5 antibodies can be used for tumor imaging diagnosis or internal radiation therapy.

Cancer vaccines: Aim to stimulate the patient's immune system to mount an immune response against CEACAM-5; related studies are ongoing.

IV. Challenges and Future Perspectives

4.1 Current Challenges

Targeted therapy toxicity: Despite low expression in normal tissues, physiological CEACAM-5 expression in colon, stomach, and other epithelial tissues may cause dose-limiting toxicities such as colitis and gastritis, especially with potent ADCs and T-cell-redirecting therapies.

Tumor heterogeneity and antigen loss: Under therapeutic pressure, CEACAM-5-negative clones may selectively expand, leading to resistance.

Inherent limitations of serum biomarkers: Lack of specificity and sensitivity for early diagnosis, necessitating combination with other markers (e.g., ctDNA).

4.2 Future Directions

Optimization of novel targeted therapies:

Conditionally activated antibodies/prodrugs: Develop "smart" ADCs or bispecific antibodies activated only in the tumor microenvironment (e.g., in the presence of specific proteases) to improve the therapeutic window.

Affinity and potency optimization: Fine-tune antibody affinity for CEACAM-5 through engineering to balance efficacy and normal tissue toxicity.

Combination therapy strategies:

Combination with immune checkpoint inhibitors: CEACAM-5-targeted therapy can reverse the immunosuppressive microenvironment, potentially synergizing with PD-1/PD-L1 inhibitors.

Combination with other targeted drugs or chemotherapy.

Integration of liquid biopsy technologies: Combine dynamic changes in serum CEA with molecular profiling of circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) for more precise real-time efficacy monitoring and resistance mechanism analysis.

Exploration of non-cancer diseases: Its role in inflammatory bowel disease is also of research interest.

Conclusion

The journey of CEACAM-5 (CEA) is a classic example of translational medicine. Starting as a pioneering serological marker for colorectal cancer diagnosis, it has evolved over half a century into one of the core molecules in the innovative wave of solid tumor-targeted therapies. With breakthroughs in clinical trials for ADC therapies like SAR408701, CEACAM-5 is proving its immense potential in the therapeutic arena. Despite challenges such as toxicity management and resistance, the exploration of exquisitely designed antibody engineering and combination therapy strategies holds promise for bringing new treatment options to patients with CEACAM-5-expressing solid tumors such as gastrointestinal cancers and lung cancer, continuing the new chapter of this classic molecule in the history of cancer treatment.